Harpoon Therapeutics Inc. (HARP)
Harpoon Therapeutics Statistics
Share Statistics
Harpoon Therapeutics has 37.6M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 37.6M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 25.56M |
| Failed to Deliver (FTD) Shares | 18.67K |
| FTD / Avg. Volume | 1.65% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.36 and the forward PE ratio is null. Harpoon Therapeutics's PEG ratio is 0.01.
| PE Ratio | -0.36 |
| Forward PE | n/a |
| PS Ratio | 0.75 |
| Forward PS | null |
| PB Ratio | 4.46 |
| P/FCF Ratio | -0.27 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Harpoon Therapeutics has an Enterprise Value (EV) of -11.53M.
| EV / Sales | -0.36 |
| EV / EBITDA | 0.17 |
| EV / EBIT | 0.13 |
| EV / FCF | 0.13 |
Financial Position
The company has a current ratio of 1.04, with a Debt / Equity ratio of 2.96.
| Current Ratio | 1.04 |
| Quick Ratio | 1.04 |
| Debt / Equity | 2.96 |
| Debt / EBITDA | -0.24 |
| Debt / FCF | -0.18 |
| Interest Coverage | 115.03 |
Financial Efficiency
Return on Equity is -1243.51% and Return on Invested Capital is -316.4%.
| Return on Equity | -1243.51% |
| Return on Assets | -91.06% |
| Return on Invested Capital | -316.4% |
| Revenue Per Employee | $709.22K |
| Profits Per Employee | $-1.49M |
| Employee Count | 45 |
| Asset Turnover | 0.43 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -594K |
| Effective Tax Rate | 0.88% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 1.55, so Harpoon Therapeutics's price volatility has been higher than the market average.
| Beta | 1.55 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 21.18 |
| 200-Day Moving Average | 10.91 |
| Relative Strength Index (RSI) | 82.72 |
| Average Volume (20 Days) | 1.13M |
Income Statement
In the last 12 months, Harpoon Therapeutics had revenue of 31.91M and earned -67.14M in profits. Earnings per share was -20.24.
| Revenue | 31.91M |
| Gross Profit | 28.82M |
| Operating Income | -68.33M |
| Net Income | -67.14M |
| EBITDA | -65.97M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -20.24 |
Balance Sheet
The company has 51.61M in cash and 16.01M in debt, giving a net cash position of 35.61M.
| Cash & Cash Equivalents | 51.61M |
| Total Debt | 16.01M |
| Net Cash | 35.61M |
| Retained Earnings | -352.52M |
| Total Assets | 47.58M |
| Working Capital | 16.19M |
Cash Flow
In the last 12 months, operating cash flow was -89.18M and capital expenditures -347K, giving a free cash flow of -89.53M.
| Operating Cash Flow | -89.18M |
| Capital Expenditures | -347K |
| Free Cash Flow | -89.53M |
| FCF Per Share | -26.99 |
Margins
Gross margin is 90.3%, with operating and profit margins of -214.08% and -210.36%.
| Gross Margin | 90.3% |
| Operating Margin | -214.08% |
| Pretax Margin | -212.22% |
| Profit Margin | -210.36% |
| EBITDA Margin | -206.7% |
| EBIT Margin | -214.08% |
| FCF Margin | -280.52% |
Dividends & Yields
HARP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -278.81% |
| FCF Yield | -371.81% |
Analyst Forecast
Currently there are no analyst rating for HARP.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Sep 5, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Sep 5, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | 0.58 |
| Piotroski F-Score | 2 |